POST Online Media Lite Edition


Arcadia Consumer Healthcare acquires Kaopectate from Sanofi

Christian Fernsby |
Arcadia Consumer Healthcare, formerly Kramer Laboratories, a recognized leader in the consumer healthcare industry, yesterday announced that is has completed the acquisition of the U.S. rights to the Kaopectate brand from Sanofi.

Article continues below


Backed by Avista Capital Partners, a leading middle-market healthcare private equity firm, Arcadia markets a diverse portfolio of consumer healthcare products including Nizoral, the fastest growing therapeutic dandruff shampoo, and Fungi-Nail, a market leader in the speciality footcare category.

With its demonstrated ability to turn around brands and drive category leading growth through investment and innovation, Arcadia also has an eye towards additional strategic acquisitions.

Kaopectate® has been a leader in the treatment of diarrhea and upset stomach for more than 75 years and has been trusted by millions of Americans during that time.

Available in both liquid and caplets, Kaopecate provides safe and effective relief and is available at all major retailers throughout the U.S.

What to read next

Sanofi-Aventis to pay €40.6 million for abusing dominant position
Sanofi sues Novo Nordisk over diabetes drugs in U.S.
Sanofi Pasteur agrees to refund $27.8 million to Philippines